The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

Management emphasized the potential for label expansion into mutant NPM1 AML and frontline settings, with an estimated $750 ...

This class of biologic may work particularly well in blood cancers with mutated nucleophosmin 1 (NPM1). The antibody may be combined with a delta opioid receptor (DOR) inhibitor and/or a menin ...

It comes a few days after the company's shares came under pressure from the results of a phase 1/2 trial of Revuforj in relapsed or refractory mutant NPM1 acute myeloid leukaemia (AML), a follow ...

Kura Oncology (KURA) announced Kura submitted a New Drug Application for ziftomenib, a highly selective, once-daily, oral, investigational ...

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...

Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq ...